(NASDAQ: ELTX) Elicio Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.45%.
Elicio Therapeutics's earnings in 2026 is -$40,185,000.On average, 6 Wall Street analysts forecast ELTX's earnings for 2026 to be -$39,065,391, with the lowest ELTX earnings forecast at -$40,775,503, and the highest ELTX earnings forecast at -$36,473,501. On average, 5 Wall Street analysts forecast ELTX's earnings for 2027 to be -$47,306,760, with the lowest ELTX earnings forecast at -$56,113,078, and the highest ELTX earnings forecast at -$35,271,078.
In 2028, ELTX is forecast to generate -$52,563,067 in earnings, with the lowest earnings forecast at -$61,724,386 and the highest earnings forecast at -$42,084,809.